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Introduction
Lung cancer is the leading cause of cancer-related death worldwide [1], with 85% of lung cancer 
being of non-small cell lung cancer (NSCLC) variety [2]. In recent years, adenocarcinoma has 
replaced squamous cell carcinoma as the commonest histological subtype of lung cancer in many 
parts of the world, including in Malaysia [3]. 
Presence of activating mutation in the epidermal growth factor receptor (EGFR) of NSCLC 
predicts clinical response to gefitinib, an oral first-generation reversible EGFR-tyrosine kinase 
inhibitor (EGFR-TKI) [4,5]. EGFR is a transmembrane glycoprotein that is coded by a gene located 
at the short arm of chromosome 7. Mutation in EGFR causes continuous tyrosine kinase activities 
that can lead to uncontrolled cellular proliferation, differentiation, migration and survival, which 
ultimately leads to lung cancer development [6]. The frequency of EGFR mutation has been found 
to be high among East Asian, women, non-smoker and adenocarcinoma subtype of NSCLC [7-9]. 
Several phase 3 clinical trials have demonstrated the superiority of EGFR-TKI over cytotoxic 
chemotherapy as first-line treatment in patients with EGFR mutant advanced NSCLC or 
adenocarcinoma in terms of response and progression-free survival [10-16]. Clinical guidelines 
recommend EGFR-TKI as first-line treatment in patients with EGFR-mutant advanced NSCLC 
[17,18]. As EGFR mutation testing is costly, understanding independent predictive factor of EGFR 
mutation become very important in prioritizing patients for this investigation. This is particularly 
true at the area with limited laboratory support and financial resources.
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Abstract
Introduction: Studies of EGFR mutation frequency in patients with non-small cell lung cancer 
(NSCLC) or lung adenocarcinoma were limited to clinical trials, convenient sample, retrospective 
studies of archived samples or studies involving advanced lung cancer only.
Methods: A cross sectional, single center, prospective study of EGFR mutation status among 
patients with newly diagnosed lung adenocarcinoma attending University Malaya Medical Center 
over a 4-year-period.
Results: Of 394 patients with adenocarcinoma, 166 (42.1%) were tested EGFR mutation-positive 
while the remaining 228 (57.9%) had EGFR wild-type tumour. Exon 19 deletion mutation was the 
most common EGFR mutation subtype (96 (24.4%)), followed by exon 21 L858R point mutation 
(64 (16.2%)). On univariate analysis, gender, smoking status and smoking pack-years (p<0.001) 
were significantly associated with EGFR mutation status. Multivariate logistic regression analysis 
identified smoking status and smoking pack-year (p<0.001) as independent predictive factors for 
EGFR mutation positivity. EGFR mutation frequency was significantly higher in never smokers 
(OR, 7.12; 95% CI, 3.79 – 13.38; p<0.001) and previous smokers (OR, 2.45; 95% CI, 1.18 – 5.09; 
p=0.016). Compared to current or previous smokers of more than 50 pack-years, those who smoked 
less than 10 pack-years (OR, 7.70; 95% CI, 2.06 – 28.74; p=0.002) and 10-20 pack-years (OR, 3.42; 
95% CI, 1.02 – 11.50; p=0.047) had significant higher frequency of EGFR mutation.
Conclusion: EGFR mutation is common in Malaysian patients with lung adenocarcinoma. A never 
smoking status is a robust independent predictor of EGFR mutation positivity. EGFR mutation rate 
was inversely related to the amount of smoking, and is significantly lower in patients who smoked 
>20 pack-years.
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